IL43764A - Oral corticosteroid preparations - Google Patents
Oral corticosteroid preparationsInfo
- Publication number
- IL43764A IL43764A IL43764A IL4376473A IL43764A IL 43764 A IL43764 A IL 43764A IL 43764 A IL43764 A IL 43764A IL 4376473 A IL4376473 A IL 4376473A IL 43764 A IL43764 A IL 43764A
- Authority
- IL
- Israel
- Prior art keywords
- corticosteroid
- layer
- prednisolone
- soluble
- corticosteroids
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims description 25
- 230000028327 secretion Effects 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000002552 dosage form Substances 0.000 claims abstract 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims abstract 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims abstract 2
- 229960000258 corticotropin Drugs 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 229960001334 corticosteroids Drugs 0.000 claims description 19
- 230000006978 adaptation Effects 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 3
- 230000033764 rhythmic process Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 12
- 210000004051 gastric juice Anatomy 0.000 abstract description 11
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract description 11
- 229960005205 prednisolone Drugs 0.000 abstract description 10
- 238000000576 coating method Methods 0.000 abstract description 9
- 230000009471 action Effects 0.000 abstract description 7
- 239000011248 coating agent Substances 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 4
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 abstract description 3
- 229960003290 cortisone acetate Drugs 0.000 abstract description 3
- 150000002148 esters Chemical class 0.000 abstract description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract description 2
- 230000027288 circadian rhythm Effects 0.000 abstract description 2
- 238000013270 controlled release Methods 0.000 abstract description 2
- 229960004544 cortisone Drugs 0.000 abstract description 2
- 229960000890 hydrocortisone Drugs 0.000 abstract description 2
- 229960004618 prednisone Drugs 0.000 abstract description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract description 2
- 230000001360 synchronised effect Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 101800000414 Corticotropin Proteins 0.000 abstract 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 abstract 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 1
- 235000021152 breakfast Nutrition 0.000 abstract 1
- 229960004584 methylprednisolone Drugs 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000008298 dragée Substances 0.000 description 21
- 239000013543 active substance Substances 0.000 description 9
- 230000002060 circadian Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960002800 prednisolone acetate Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004922 lacquer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940051868 antimigraine drug corticosteroid derivative Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2260384A DE2260384C3 (de) | 1972-12-09 | 1972-12-09 | Oral zu applizierendes Corticosteroid-Präparat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL43764A0 IL43764A0 (en) | 1974-03-14 |
| IL43764A true IL43764A (en) | 1977-03-31 |
Family
ID=5864005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL43764A IL43764A (en) | 1972-12-09 | 1973-12-06 | Oral corticosteroid preparations |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS4986527A (de) |
| KR (1) | KR780000243B1 (de) |
| AT (1) | AT345983B (de) |
| BE (1) | BE808442A (de) |
| CA (1) | CA1027864A (de) |
| DE (1) | DE2260384C3 (de) |
| FR (1) | FR2209585B1 (de) |
| GB (1) | GB1458676A (de) |
| HU (1) | HU171907B (de) |
| IE (1) | IE38614B1 (de) |
| IL (1) | IL43764A (de) |
| NL (1) | NL7316585A (de) |
| ZA (1) | ZA739327B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002074316A1 (en) * | 2001-03-15 | 2002-09-26 | Enteron Pharmaceuticals, Inc. | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| WO2005102287A2 (en) | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| NZ595428A (en) * | 2009-04-07 | 2013-04-26 | Duocourt Pharma Ab | Improved glucocorticoid therapy |
| CN107252488A (zh) | 2009-10-01 | 2017-10-17 | 艾戴尔医药公司 | 口服给予的皮质类固醇组合物 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB862376A (en) * | 1957-10-10 | 1961-03-08 | Pfizer & Co C | Sustained release pharmaceutical tablet |
-
1972
- 1972-12-09 DE DE2260384A patent/DE2260384C3/de not_active Expired
-
1973
- 1973-12-03 FR FR7343036A patent/FR2209585B1/fr not_active Expired
- 1973-12-03 KR KR7302039A patent/KR780000243B1/ko not_active Expired
- 1973-12-04 NL NL7316585A patent/NL7316585A/xx not_active Application Discontinuation
- 1973-12-06 IL IL43764A patent/IL43764A/en unknown
- 1973-12-06 HU HU73HO00001633A patent/HU171907B/hu unknown
- 1973-12-06 CA CA187,580A patent/CA1027864A/en not_active Expired
- 1973-12-07 IE IE2216/73A patent/IE38614B1/xx unknown
- 1973-12-07 ZA ZA739327A patent/ZA739327B/xx unknown
- 1973-12-07 AT AT1026773A patent/AT345983B/de active
- 1973-12-08 JP JP48137285A patent/JPS4986527A/ja active Pending
- 1973-12-10 BE BE138701A patent/BE808442A/xx unknown
- 1973-12-10 GB GB5709073A patent/GB1458676A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE38614B1 (en) | 1978-04-26 |
| JPS4986527A (de) | 1974-08-19 |
| CA1027864A (en) | 1978-03-14 |
| GB1458676A (en) | 1976-12-15 |
| DE2260384B2 (de) | 1979-04-12 |
| IE38614L (en) | 1974-06-09 |
| NL7316585A (de) | 1974-06-11 |
| BE808442A (fr) | 1974-06-10 |
| AU6328073A (en) | 1975-06-12 |
| KR780000243B1 (en) | 1978-07-01 |
| DE2260384C3 (de) | 1979-11-29 |
| HU171907B (hu) | 1978-04-28 |
| DE2260384A1 (de) | 1974-06-12 |
| ATA1026773A (de) | 1978-02-15 |
| FR2209585A1 (de) | 1974-07-05 |
| AT345983B (de) | 1978-10-10 |
| ZA739327B (en) | 1974-10-30 |
| FR2209585B1 (de) | 1977-09-02 |
| IL43764A0 (en) | 1974-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4066756A (en) | Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin | |
| US4587118A (en) | Dry sustained release theophylline oral formulation | |
| US4308251A (en) | Controlled release formulations of orally-active medicaments | |
| US6117450A (en) | Method of making a perorally administered solid drug with controlled effective ingredient delivery | |
| JP4354667B2 (ja) | 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ | |
| CA1302272C (en) | Pharmaceutical compositions containing dipyridamole or mopidamol and o-acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and theiruse in treating clot formation | |
| US4806361A (en) | Medicaments in sustained release unit dose form | |
| CA2815959C (en) | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms | |
| KR20060015528A (ko) | 정해진 핵 위치를 가지는 서방성 정제 | |
| AU4643493A (en) | Multiparticulate pulsatile drug delivery system | |
| GB2204241A (en) | Fat coated pharmaceutical compositions | |
| US2970082A (en) | Aluminum nicotinate compositions for hypercholesteremia | |
| JP2967492B2 (ja) | 腸内適所放出経口製剤 | |
| IL43764A (en) | Oral corticosteroid preparations | |
| DK158599B (da) | Allergenpraeparat til oral administration | |
| Tumuluri | Pharmaceutical mini-tablets: a revived trend | |
| CA1099641A (en) | Pharmaceutical composition containing chromone derivatives | |
| BG65204B1 (bg) | Фармацевтичен състав, фармацевтичен кит и използването им като противозачатъчно средство | |
| US4042698A (en) | Treatment of myasthenia gravis and oral medication therefor | |
| JPS5845403B2 (ja) | 補酵素ｑを主成分とする膵機能亢進剤 | |
| TW202241412A (zh) | 製劑 | |
| JPS63145232A (ja) | コレステロール代謝変化治療用薬剤 | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
| TWI744858B (zh) | 治療精神疾病之控釋藥物組合物和方法 | |
| CA2166427A1 (en) | Use of bile acids for preparing medicaments for the treatment of skin diseases |